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Efficacy of baths with mineral-medicinal water in patients with fibromyalgia: a randomized clinical trial
Summary:
The layout of this study, designed as a randomized crossover clinical trial, is to evaluate the efficacy  of an
intervention  with  mineral-medicinal  water  from  As  Burgas  (Ourense)  in  patients  suffering  from
fibromyalgia. Pre-intervention: randomization of group A and group B. Intervention: Phase 1: Group A: 14
baths  in  thermal  water  for  a  month  and  standard  pharmacological treatment;  group  B,  standard
pharmacological treatment. Rest period, 3 months.  Phase 2: Gruop A, standard treatment and Grou B, 14
baths in thermal water for a month plus standard treatment. The Fibromyalgia Impact Questionnaire (FIQ)
was used; this grades from 1 (minimum) to 10 (maximum) the impact of the illness, which was measured in
both phases. 25 patients were included in each group and the study was concluded with 20 patients in group
A and 20 in group B. The intervention group obtained, once the baths finished, a mean score of 60,3 (±11,8)
and the control group of 70,8 (±13,0) (p <0,001). Three months later, the intervention group presented a
mean score of 64,4 (±10,6) and the control group of 5,0 (±11,3) (p <0,001). We can therefore conclude that
the simple baths with mineral-medicinal water from As Burgas can make an improvement on the impact
caused by fibromyalgia.
Keywords
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INTRODUCTION
Fibromyalgia  is,  still  nowadays,  a  syndrome  with  little  known  aetiology,  characterized  by  generalized
skeletal  muscle  pain  accompanied  by  other  diverse  symptoms,  such  as  fatigue,  sleep  disturbances  and
anxiety  and  depression  issues,  among  others  (Wolfe  et  al.  2013).  Its  treatment  is  usually  complex
(Macfarlane et al., 2017) and, in many occasions, unsatisfactory, placing the FM as a public health problem
due to the significant health expenditure generated, which is mainly translated in a high rate of medical
consultations and a high consumption of drugs (Arnold et al., 2018).
Taking into account the chronicity and idiopathic origin of this syndrome, the primary aim of treatment
should be focused on improving the quality of life of patients, and evidence makes clear the need to combine
pharmacological treatments with non-pharmacological ones (Häuser et al., 2012). Among these last ones,
balneotherapy has been proved an effective strategy in the treatment of chronic pain (Morer et al. 2017;
Karagulle et al 2017). It is a safe therapeutic option, with little adverse effects (Langhorst et al., 2009) and
usually well tolerated by patients, providing analgesia, sedation and muscular rejuvenation (Naumann et al.
Sadaghiani, 2014), which has great importance in this pathology.
The main aim of this study is to assess the efficacy of an intervention with mineral-medicinal  water in
patients with fibromyalgia, which could lead to a clinically relevant reduction in parameters of affectation at
the end of the intervention and after one month, measured with the Fibromyalgia Impact Questionnaire
(FIQ). As secondary objectives, positive changes in hemodynamic variables (systolic, diastolic and pulse
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pressure), drug consumption and allodynia will be evaluated.
MATERIALS AND METHODS
Study design and patient selection:
A randomized crossover  clinical  trial  (RCT) was proposed,  being developed between January 2016 and
January  2017.  The  study  was  approved  by  the  Autonomous  Committee  of  Research  Ethics  of  Galicia
(Registration Code 2016/362).
Patients were invited to participate by the doctors and nurses from a health centre in the city of Ourense. In
case of acceptance, an appointment to a consultation with two nurses that were members of the research
team, would be set. Once there, they would be provided with the information sheet and the informed consent
form that  needed to be signed. At that point the measurements would be taken. Furthermore, they were
provided with health education guidelines, emphasizing the benefits of the abandonment of certain harmful
behaviours, especially sedentary lifestyle.
Participants: inclusion and exclusion criteria
Male and female patients aged between 18 and 65 and diagnosed with FM according to the criteria of the
American College of Rheumatology of 2010, were included (Wolfe et al., 2010), excluding those who had
absolute or relative contraindications for taking baths of MM water: acute phase illnesses, tumours, cardiac,
respiratory or renal terminal insufficiencies, severe metabolic disorders, severe or decompensated arterial
hypertension  and  recent  cerebrovascular  accidents,  also  post-traumatic  and  postoperative  processes,
hypotension, vascular pathologies, history of fractures due to osteoporosis or uncontrolled thyroid diseases
(Bazzichi et al 2013, Fazaa et al 2014, Bağdatlı et al 2015, Branco et al 2016, Fioravanti et al.2018). We also
excluded patients  who had  taken  baths  with  MM water  during  the  last  year,  those  who suffered  from
psychiatric or cognitive disorders, had a disability that limited their participation, pregnant women, those
who had taken part in other clinical trial and patients who did not consent to participate.
Intervention
The sample was randomly divided into two groups: group A and group B. The study was, likewise, divided
into two phases:
Phase 1: The patients of group A took 14 baths, 30 minutes long for a month, in bicarbonated sodium water
of medium mineralization, alkaline, lithic, fluorinated, silicated, with a temperature of 38ºC in the thermal
and public  pool of As Burgas (Ourense),  while  they carried on taking the treatment prescribed by their
doctor. On the other hand, patients in group B only followed the usual pharmacological treatment prescribed
by their doctor that they were already taking before the study commenced.
The two groups were subjected to four measurements:  baseline, a measurement when group A finished the
baths, another one a month later and the last one, three months after receiving the baths. Subsequently, the
entire sample maintained a 3-month washout period. This washout period was planned so that there were no
residual therapeutic effects of the baths in Group A before starting the second phase of the trial, and it was
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made based on other study results (Bağdatlı et al., 2015, Koçyiğit et al., 2016), all of them RCTs of parallel
groups, since no studies with a cross design tat could be used as a model were found.
Phase 2: Once the washout period was completed, the baseline measurements were again collected from the
two groups of participants. Subsequently, the groups were crossed. Thus, only group A carried on with its
usual pharmacological treatment and patients from group B received the same intervention in As Burgas
thermal pool as group A in the first phase, in addition to continuing with the treatment prescribed by the
doctor. The two groups were once again measured at the end of group B baths, 1 month after and 3 months
later.
From the  beginning  of  the  study and  throughout  it,  and  with  the  aim  of  not  masking  the  pain,  clear
instructions were given to the patients to not take symptomatic drugs 1 one day before the different check-
ups. Likewise, they were told to not start any non-pharmacological therapy that could alter the results of the
study.
Studied variables
Sociodemographic and epidemiological data, such as sex, age, marital status, studies, occupation, smoking
habits or body mass index, were collected.  As a primary outcome, the clinically relevant reduction in the
affectation  parameters  was  suggested,  being  this  measured  with  the  FIQ.  As  secondary  outcomes,  we
considered the positive changes in the hemodynamic variables (systolic and diastolic blood pressure and
heart  rate  measured  with the Omrom M-2 tensiometer),  the  intake of  drugs for  FM (grouping them in
analgesics, antidepressants, anticonvulsants and muscle relaxants) and allodynia, measured with the Omrom
M-2 blood pressure cuff, which measures the intensity of the stimulus needed to produce pain and, the lowest
this is, the highest is the allodynia index (Chandran et al 2012; Cassis et al 2014). To measure the primary
outcome,  the  fibromyalgia  impact,  the  FIQ  questionnaire  was  used. This  questionnaire  is  a  validated
instrument that assesses the impact of fibromyalgia over physical capacity, such as subjective signs closely
related to this syndrome (Salgueiro et al. 2013). The scoring range goes from 1 to 100, with 1 being the
highest functional capacity and quality of life (minimum impact of fibromyalgia) and 100 the maximum
impact.
Sample size and randomization
The sample size was calculated based on the study by Bagdatli et al. (2015), in which an average FIQ score
of 51.2 points was observed in the experimental group before the intervention and a reduction of the score
close to 12 points after the intervention. According to this, we estimated an average post-intervention FIQ
score of 39.0 points and standard deviation of the difference of 18.0 points. Under these assumptions, to
achieve a power of the 80% to detect differences in the contrast of the hypothesis by a comparison test of
means for two related samples, taking into account a level of significance of 5%, 20 pairs of subjects were
needed in the study. Assuming a percentage of losses and/or dropouts of 20%, it was necessary to recruit 25
pairs of subjects. The recruitment period was carried out during the months of January and February 2016.
The first 50 patients who met the inclusion criteria and who agreed to participate were included in the study.
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For the allocation of patients to one of the two groups, a randomization list generated automatically by an
outside collaborator was used, keeping the sequence hidden for the research team until the intervention was
assigned. The study was open, so there was no blinding of the participants or the researchers regarding the
assigned group, nor in the evaluation of the results. However, monitoring was carried out by internal and
external auditors to guarantee the quality of the data.
Statistic analysis
Descriptive analyses were performed  (expressing the continuous variables in mean and standard deviation
(SD) and qualitative variables in absolute numbers and percentages) and comparison tests (Student's t test for
independent  and paired samples  and McNemar test),  as  well  as  normality  tests  of  continuous  variables
(Shapiro-Wilks test). If the last ones did not present a normal distribution, the non parametric tests of Mann-
Whitney and Wilconxon were used. Intention-to-treat analyses were conducted to keep the advantages of
randomization  regarding  known or  unknown variables  that  could  influence  the  results,  and  analysis  by
protocol. The study losses were analysed separately. The analyses were performed with the software SPSS
version 19.
RESULTS
Of the 191 men and women from the health centre diagnosed with FM, 106 (75.2%) did not meet the
inclusion criteria, 20 (14.2%) could not be contacted and 15 (10.6%) did not accept to participate. 50 were
the individuals that started the study, finalizing 41 of them, with a total percentage of losses of the 18%, (4
subjects in group A and 5 subjects in group B), not observing significant differences between the lost sample
and the one that carried on with the study. Amongst the lost cases, 6 f them left due to work causes, 2 due to
illness and 1 due to pregnancy. Figure 1 shows the flow of participants in each stage of the trial according to
the CONSORT diagram.
The subjects were mostly women, 48 (96%), with an average age of 52.9 ± 9.9, were married or lived as a
couple 35 (70%), had secondary school education 29 (58%) and 25 (50%) were active (50%). Their mean
BMI was 28.1 ± 4.6, 13 of the subjects smoked (26%), and had an average evolution of the disease of 14.2
years since the diagnosis ± 4.0.
Initially, the homogeneity of the sample was checked after the random assignment of the subjects in the 2
groups, not observing statistically significant differences between them, except the systolic blood pressure (p
= 0.026), the intake of muscle relaxant drugs (p = 0.042) and the intake of anticonvulsant drugs (p = 0.047)
(table 1).
Intra-groups comparison
FIQ results
By analysing group A results in the two phases of the study, we can observe that in both, first and second
phases,  the FIQ score means after  the 3 month washout period, have remained statistically significantly
lower than the baseline mean in the first phase; except the last measurement 11 months after receiving the
baths. In the first phase of the study, group A baseline mean was 79.4 ± 10.2, being 61.9 ± 13.0 (p <0.001) at
the end of the baths; 66, 3 ± 12.9 (p <0.001) one month after and 64.2 ± 11.0 (p <0.001) tree months later.
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During the second phase, when group A was the control, the score was 64.4 ± 8.7 (p <0.001) after  the
baseline measurement (performed 6 months after receiving the baths). The following measurement in this
group, 7 months after receiving the baths, was 64.6 ± 11.5 (p <0.001), the next one, 8 months later, was 68.2
± 12.3 (p = 0.002) and the last measurement, 11 months after receiving the baths, was 74.0 ± 10.0 (p =
0.070).
On the other hand, group B FIQ score means, being this group not subjected to any intervention during the
first phase of the study, did not show significant changes, with a baseline measurement of 74.2 ± 11.3 at the
beginning of the study, 77.4 ± 11.3 (p = 304) when group A finished the baths, 73.8 ± 17.5 (p = 0.936) one
month after and 76.2 ± 12 , 8 (p = 0.551) three months later. During the second phase of the study, the
baseline measurement after the washout period was 77.3 ± 6.7 (p = 0.145). It was during this phase when
both groups were crossed, being group B the intrvention target with mineromedicinal water baths. Thus, just
at the end of the baths the average score was 58.7 ± 10.5 (p <0.001); 63.7 ± 9.8 (p = 0.002) one month after
and 64.7 ± 10.6 (p = 0.020) three months later.
Allodynia results
On top of this, the allodynia results in group A also showed significant changes like the FIQ ones; however,
as it can be observed in figure 3.
A carry-over  effect  was  observed  in  the  design  of  the  study,  since  group  A,  the  one that  started  the
intervention with baths in Phase 1, maintained, after the bleaching period in the second phase of the study, in
the which it acted as control group, improvements in both aspects,  since the differences in the FIQ and
allodynia means were significant, compared with the first baseline measurement in the first phase, as it can
be observed in figures 2 and 3.
Inter-groups comparison
FIQ results
The main objective of the study, the impact of fibromyalgia measured with the FIQ questionnaire in the three
measurements carried out (just after the baths, one month and three months later) to the two groups (control
and intervention with baths) during both phases (first and second), show that the impact on the group that
was taking the baths was always lower (table 2 and figure 4). The average score in the control group at the
end of the baths was 70.9 ± 13.0 and 60.4 ± 11.8 in the group taking the baths (p <0.001). The mean score
was 71.3 ± 15.1 in the control group a month later and 65  in the group taking the baths ± 11.4 (p <0.001).
Three months after the baths were finished, the control group showed an average score of 75.0 ± 11.4 and the
group that took the baths, of 64.4 ± 10.7 (p <0.001).
Allodynia results
In regards to one of the secondary objectives, the improvement or increase of the mean in the allodynia data,
we were able to observe that just at the end of the baths and one month later, both groups did not show
statistically significant differences. However, three months after the intervention the group subjected to the
baths presented a significant improvement against the other group, as it can be observed in table 2 and figure
5.
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Regarding the other variables, such as hemodynamic values and drug intake, no significant differences were
observed in the different measurements carried out throughout the study.
DISCUSSION
In the present study, after the administration of a protocol of baths with MM water to patients diagnosed with
FM, a significant improvement in the impact caused by the disease was found. This was measured with the
FIQ questionnaire several months after the intervention. Our study is the first one to use a crossover RCT
design to measure the therapeutic use of MM baths in patients with fibromyalgia. The choice of this type of
design was to give scientific value to a type of co adjuvant therapy that, in our environment and until now,
has not been taken into sufficient consideration by health professionals.
A consensus on the therapeutic management of fibromyalgia has been reached (McFarlane et al.,  2017),
highlighting  the  importance  of  the  multidisciplinary  approach  and  giving  special  emphasis  to  non-
pharmacological treatments; and even more recently, an evidence-based diagnostic system for this illness has
been established, based on the ACTTION-APS taxonomy (Arnold et al., 2018).  This taxonomy includes
mechanisms,  common  characteristics,  comorbidities  and  diagnostic  criteria  that  could  improve  the
recognition of FM in clinical practice.
FM has been suggested to be a clinical manifestation of central nervous system hypersensitivity (Yunus et
al., 2008), being this hypersensitivity the main mechanism involved in the development and maintenance of
chronic pain (Woodman, 2013). There is evidence of altered central pain pathways, suggesting that stress
peptides  that  trigger  the  release  of  inflammatory  and  neurosensitising  mediators  take  part  in
neuroinflammation (Theoharides et al., 2015). The immersion in mineral-medicinal water has been proved to
cause  physiological  effects  both  locally  and  generally,  exerted  by  physical,  chemical  and  biological
mechanisms (Fioravanti et al., 2011; Galvez et al., 2018). Perhaps for this reason, the temperature rise and
the effect of hydrostatic pressure generated by thermal baths can produce analgesia by increasing the pain
threshold (Ardic et al., 2007). These findings have been confirmed by other investigators by pointing out that
in  patients  with  fibromyalgia,  a  protocol  of  baths  with  water  MM,  can  reduce  certain  mediators  of
inflammation and pain, and that this may be due to the chemical components of the water (Guidelli et al.
2012).  If  we add  to  these properties  its  possible  antioxidant  action,  we  would have  the  answer  to  the
therapeutic benefit observed (Prandelli et al. 2013).
Balneotherapy deserves  to  be  currently  considered  as  another  therapy in  the  treatment  of  fibromyalgia
(Forestier et al., 2017) and along this line are the studies developed by different authors. Kocyigit et al.
(2016) carried out an RCT in a spa with 61 participants,  all of which were provided with health education
guidelines. The members of the intervention group were given a series of 21 mineromedicinal water baths of
20  minutes  of  duration  5  days  a  week.  The  control  group  carried  on  with  the  usual  treatment.  Pre-
intervention measurements were carried out, and also after15 days, a month and 3 and 6 months later, finding
a significant improvement in the impact caused by the disease  on the group having the baths against the
control group up to 3 months after the intervention. 100 patients took part in the studyby Fioravanti et al.
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(2018) it was also carried out in a spa and measurements were taken in the same time intervals as those by
Kocyigit; however, there were no more similarities between the two studies. This has been the first double
blind study on FM balneotherapy that has been done so far. The intervention group received 12 baths with
MM water for 2 weeks. The baths had a duration of 15 minutes followed by a 15 minute rest. On the other
hand, the control group also received 12 baths of 15 minutes duration and 15 minutes rest, but the baths
were,  in this case, in hot potable water that was applied a dye to simulate the color of the mineral-medicinal
water.  In  the  results,  they  found significant  differences  between  both  groups  up  to  6  months  after  the
experiment.
Our results were also along line with other literature. Over three follow up months, the group that received
the baths showed significant improvement compared to the control group.  However,  in our study, as an
unforeseen finding and due to circumstances related to the design, improvement was also found after the
intervention with significant results up to 8 months after it. In crossed RCTs, the tested effect must occur
quickly and have a short duration, in addition to remaining stable during the two periods of the study. When
choosing the design and adjusting the measurement periods and washout, other works were analyzed, all of
them RCTs of parallel groups, since, as we have mentioned previously, we could not find studies with a
crossover design that could serve us as a model. The consulted works carried out measurements 3 months
after the interventon (Neumann et al., 2001; Buskila et al., 2001; Altan et al., 2004; Nugraha et al., 2011;
Özkurt et al., 2012; Bağdatlı. et al., 2015), 4 months (Fioravanti et al., 2007), 6 months (Evcik et al., 2002;
Koçyiğit et al.,  2016; Fioravanti et al., 2018) and only in one study the measurements were repeated  9
months later (Dönmez et al., 2005). In all these studies, it was possible to maintain a 3 month therapeutic
effect mainly, reaching a maximum of 6 months in those mentioned above. For this reason, we proposed a 3
month washout period in the design of this study, in order to avoid residual therapeutic effects of the baths in
group A before starting the second phase of the trial. Therefore, patients in this group spent 6 months from
the time they received the baths in the first phase of the study until the end of the washout period, which,
according to the scientific findings made up to that moment, seemed initially enough time. However, this
was not the case, given that this beneficial effect was maintained significantly up to 8 months after finishing
baths with MM waters, reaching up to 11 months later (difference not statistically significant but clinically
relevant). This finding revealed the inadequate design of the study. However, on the other hand, we found
that simple baths in a public pool with MM water, maintained good therapeutic results for a longer period of
time than in the previously mentioned studies, which leads us to affirm that MM water improved the FM
symptoms in a group of patients and that this improvement could last up to 8 months.
This is the first international study that has been designed as a RCT in patients suffering from fibromyalgia,
where the effect of the baths and the control are assessed in the same individual, obtaining this way a lower
variability than if the comparison of the effect was performed in different subjects, as it is the case of parallel
RCTs. However, until the present work, no parallel studies had been carried out in Spain either.
On the other hand, both the controls and the experimental group in a large number of the published studies,
were accommodated and received the different types of interventions in spas. It has been shown that patients
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who abandon their daily routine and are in a different environment, such as a spa, interacting and socializing
with other patients can feel an improvement in the pathological processes they suffer (Baysal et al., 2018).
However, in our study, the participating subjects received the baths in a public thermal pool, accessible to
any citizen and to which they came only for this therapeutic activity. This last aspect of accessibility, despite
being characteristic of the city where the study was carried out, is relevant from a healthcare point of view,
since  it  outlines  the  possibility  for  health  professionals  of  using  these  thermal  baths  as  a  contributing
therapeutic resource for certain pathologies.
Among the limitations of the study, we find the lack of blinding of the patients due to it not being allowed by
the intervention, since the city where it was developed, has no other spaces like the free mineral-medicinal
water springs, which just have hot potable water. Another aspect is that the sample studied was not very
large, but it was still possible to detect significant differences, since the proposed design allows the same
sample to work with greater statistical power. On the other hand, the washout time was proven not to be
sufficient, situation that caused a carry-over effect. Nevertheless, this methodological failure facilitated the
verification of the long duration of the therapeutic effect provided by the MM waters. It could be interesting
to carry out a follow-up of the sample to deepen in the therapeutic effect  that  MM water has over this
pathology.
In conclusion, the impact caused by FM has been improved in this study by an intervention of 14 half hour
baths with MM water in patients diagnosed with the illness and the improvement has lasted significantly for
8 months.
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